MVM was founded in 1997 and manages several funds. MVM's latest fund totals more than $200 million. MVM has a global perspective on healthcare and maintains offices in Boston and London.
MVM invests broadly across the healthcare sector, including in specialty pharmaceuticals, medical technology, diagnostics, life science tools, consumer healthcare, veterinary medicine, healthcare services, and digital health.
Alliance Pharma plc (AIM: APH), the specialty pharmaceutical company, announces that, following discussions with the Medicines and Healthcare products Regulatory Agency and the Commission on Human Medicines, the Marketing Authorisation Application for Diclectin® is now considered approvable.
Alexion Pharmaceuticals, Inc., has today, through Alexion Pharma Nordics Holding AB, announced a public cash offer to Wilson Therapeutics’ shareholders for a consideration of SEK 232 per Wilson Therapeutics share in cash (the “Offer”), which corresponds to a total offer value of approximately SEK 6,564 million, based on 28,292,272 shares outstanding.